ACEI及ACEI与ARB联用治疗心力衰竭临床对比

A Clinical contract for ACEI with Combination ACEI and ARB in the Treatment of Heart Failure

目的观察ACEI类药物在治疗充血性心力衰竭(CHF)的临床疗效及ACEI类药物与ARB类药物联用在治疗充血性心力衰竭(CHF)的临床疗效。方法两组均给治疗原发病及给与常规纠正心衰用药的基础上,对照组给卡托普利(ACEI),治疗组给卡托普利〈ACEI)及科素亚(ARB)。从小剂量开始,卡托普利6.25mg/次,3次/d,科素亚50mg,l次/d。根据患者的耐受程度加大剂量,治疗观察时间为一个月。结果ACEI组和ACE及ARB联用组治疗心衰的临床效果无统计学意义(P>0.05),无统计学意义。结论ACEI及ARB联用运用并未增加疗效。

Objective To observe the clinical effectiveness of ACEI and the combination application of ACEI and ARB in the treatment of heart failure. Methods All 160 patients with Heart Failure disease were at random divided as trial group（ 80 cases）and control group （80 cases）. The two groups were administered routine medical treatment for primary disease and heart failure, and the patients in control group were administered ACEI. The patients in trial group were administered combination ACEI and ARB. From a low dose on （ACEI, 6. 25 mg, tid; ARB ,50 mg, qd）, add the dose by patients＇ tolerance. Results there was no significant difference between the two groups （ P 〉 0.05 ）, there was not a statistically significant. Conclusion there was no better therapeutic effect for combination application of ACEI and ARB than only ACEI in the treatment of heart failure.